Amylyx Pharmaceuticals In... (AMLX)

AI Score

Unlock

4.93

0.70 (16.55%)

At close: Apr 22, 2025, 3:59 PM

4.86

-1.46%

After-hours: Apr 22, 2025, 07:56 PM EDT

Amylyx Pharmaceuticals Balance Sheet Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q1 2021	Q4 2020
Period Ending	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Mar 31, 2021	Dec 31, 2020
Cash & Equivalents	77.39M	71.84M	75M	170.55M	170.2M	135.26M	247.76M	114.56M	62.53M	107.73M	67.44M	110.4M	50.19M	76.68M	-12.88M	12.88M
Short-Term Investments	99.11M	162.56M	234.81M	202.74M	201.16M	219.79M	109.52M	231.11M	284.42M	54.86M	139.24M	144.8M	45.93M	49.02M	25.75M	n/a
Long-Term Investments	n/a	n/a	719K	719K	719K	25.05M	18.45M	10.79M	719K	719K	419K	419K	189K	n/a	n/a	189K
Other Long-Term Assets	1.47M	1.92M	479K	493K	45.66M	476K	466K	466K	466K	1.03M	456K	456K	3.44M	189K	-12.88M	125K
Receivables	447K	1.73M	4.09M	20.35M	40.05M	29.35M	33.47M	17.55M	15.31M	137K	n/a	n/a	n/a	n/a	n/a	n/a
Inventory	n/a	n/a	n/a	1.00	38.32M	32.37M	24.86M	13.07M	9.77M	563K	n/a	n/a	n/a	n/a	n/a	n/a
Other Current Assets	12.48M	9.14M	100K	16.89M	14.93M	17.34M	800K	12.75M	10.11M	570K	9.46M	10.28M	3.44M	1.72M	n/a	n/a
Total Current Assets	189.43M	245.26M	326.72M	410.53M	464.67M	434.11M	427.39M	389.05M	382.13M	171.63M	216.14M	265.49M	101.51M	129.94M	12.88M	13.64M
Property-Plant & Equipment	2.73M	3.53M	4.24M	5.71M	6.41M	6.95M	7.28M	7.65M	8.13M	8.07M	8.23M	8.07M	474K	329K	n/a	151K
Goodwill & Intangibles	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Total Long-Term Assets	4.2M	5.45M	5.44M	6.92M	52.79M	32.47M	26.19M	18.91M	9.32M	9.81M	9.1M	8.95M	4.1M	518K	-12.88M	465K
Total Assets	193.63M	250.71M	332.16M	417.46M	517.45M	466.58M	453.59M	407.96M	391.45M	181.44M	225.24M	274.44M	105.61M	130.46M	n/a	14.1M
Account Payables	2.94M	1.49M	4.96M	21.45M	22.06M	6.37M	24.7M	10.77M	6.26M	7.05M	8.12M	10.04M	4.37M	3.03M	n/a	3.61M
Deferred Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Short-Term Debt	n/a	n/a	n/a	2.31M	2.26M	2.2M	n/a	2.09M	n/a	1.99M	1.79M	1.41M	n/a	263K	n/a	n/a
Other Current Liabilities	9.99M	50.46M	n/a	59.36M	38.68M	22.95M	7.95M	31M	n/a	12.62M	8.99M	11.27M	n/a	n/a	n/a	n/a
Total Current Liabilities	28.41M	53.91M	70.08M	91.64M	82.04M	45.62M	64.08M	49.52M	46.61M	32.65M	27.16M	27.71M	17.4M	15.15M	n/a	7.33M
Long-Term Debt	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1.43M
Other Long-Term Liabilities	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	35K	239.35M	n/a	69.89M
Total Long-Term Liabilities	463K	595K	772K	1.38M	1.98M	2.57M	3.14M	5.79M	4.24M	4.77M	5.29M	5.79M	239.39M	239.38M	n/a	73.5M
Total Liabilities	28.87M	54.51M	70.85M	93.02M	84.02M	48.18M	67.22M	55.31M	50.85M	37.41M	32.45M	33.49M	256.78M	254.53M	n/a	80.83M
Total Debt	1.98M	2.57M	3.14M	3.69M	4.24M	4.77M	5.29M	5.79M	6.28M	6.76M	7.07M	7.19M	n/a	263K	n/a	1.43M
Common Stock	7K	7K	7K	7K	7K	7K	7K	7K	7K	6K	6K	6K	1K	1K	n/a	1K
Retained Earnings	-606.69M	-569.15M	-496.44M	-423.74M	-304.95M	-309.68M	-330.57M	-352.65M	-354.22M	-311.52M	-257.76M	-203.69M	-155.84M	-127.5M	n/a	-67.91M
Comprehensive Income	-92K	641K	-97K	-77K	197K	-151K	-72K	25K	-86K	-725K	-196K	-151K	9K	-1K	-66.72M	-72.06M
Shareholders Equity	164.76M	196.2M	261.31M	324.44M	433.43M	418.4M	386.37M	352.65M	340.61M	144.03M	192.79M	240.95M	-151.17M	-124.07M	5.34M	-66.72M
Total Investments	99.11M	162.56M	235.53M	203.46M	201.16M	219.79M	109.52M	231.11M	284.42M	54.86M	139.24M	144.8M	45.93M	49.02M	25.75M	189K